AI
Saturday, April 29, 2023 7:08:36 PM
OJ,
The sample size is small. But the results seem like statistically significant.
I assume in the combo trial, anytime we talk about ATL-D, by default it means DCVax-L + Poly-ICLC.
The results from the slide show that the data from the preclinical work points to the right direction. I feel excited anytime I think about what results we will see if CSF1R-I is added to the current combination. Maybe a final cure for glioblastoma.
The sample size is small. But the results seem like statistically significant.
I assume in the combo trial, anytime we talk about ATL-D, by default it means DCVax-L + Poly-ICLC.
The results from the slide show that the data from the preclinical work points to the right direction. I feel excited anytime I think about what results we will see if CSF1R-I is added to the current combination. Maybe a final cure for glioblastoma.
